Cocrystal Pharma, Inc. · NASDAQ:COCP
Cocrystal Pharma — Investor Presentation (February 2020)
32 slides from Cocrystal Pharma's investor presentation, Feb 18, 2020
Slide 1: Investor Presentation February 2020
CCRYSTAL Investor Presentation PHARM Av, INC. February 2020
Slide 2: Forward Looking Statements
uN }@ Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding expected results of our collaboration with Merck Sharp & Dohme Corp. (“Merck”), including the expected acc
Slide 3: Cocrystal's Seasoned Senior Leadership
Ake Lot Cocrystal’s Seasoned Senior Leadership Manageme! Gary Wilcox, Ph.D. Chairman and Chief Executive Officer + Over 35 years of executive biotech leadership experience and played a key role in the development of Cialis Sam Lee, Ph.D. President + Over 20 years of anti-infective drug discovery res
Slide 4: Corporate Overview
Ake Corporate Overview IGt com Clinical Stage Antiviral Company Influenza Proprietary Drug Hepatitis Discovery Platform Merck Influenza Collaboration Norovirus Gastroenteritis
Slide 5: Technology and Drug Discovery Platform
Ake Lot Technology and Drug Discovery Platform Technology Platform Based on Nobel Prize-winning technology + Near-atomic resolution + X-ray quality crystal production + Drug pocket selection + Hit-to-lead process + Lead optimization + Drug candidates Drug Discovery Platform Crystal Production Expres
Slide 6: Robust Development Pipeline
Ake Lot Robust Development Pipeline Program Discovery | Prec! Phase1 | paseza Phase2> Phase3 CC-31244- mney univers a (HCV) University of MD (Pan-genotypic NS5B NNI) CC-42344 (Influenza A PB2 Inhibitor) Influenza Influenza A/B inhibitor Noro Polymerase Norovirus ne Inhibitor
Slide 7: Merck/Cocrystal Team Initiates Influenza Collaboration
Ake Lot Merck/Cocrystal Team Initiates Influenza Collaboration Received $4 million upfront payment, eligible to receive up to $156 million in milestone payments and royalties (undisclosed) on product sales Exclusive license and collaboration agreement to discover and develop certain proprietary infl
Slide 8: Overview | Antiviral Programs: Hepatitis C
Overview | Antiviral Programs: Hepatitis C
Slide 9: Cocrystal's HCV Strategy
Ake Lot Cocrystal’s HCV Strategy Lead program CC-31244, in ongoing Phase 2a study for the treatment of Hepatitis C Current HCV Market Overview AbbVie’s Mavyret™ Demonstrated Shorter Treatment * Clinical limitations of existing long-term HCV therapies: + Approved broad spectrum HCV combination therap
Slide 10: HCV Is Still a Global Issue
RAS Lol HCV Is Still a Global Issue 71 Million oN) people die annually i 1 people infected globally (a APIS Only 20% Only 2% of infected patients of infected patients have been diagnosed! are being treated’ 1: Polaris Observatory, 2019 10
Slide 11: Hepatitis C Treatment Market Share
Ake Lot Hepatitis C Treatment Market Share 2017 Annual Sales: $12.69 Billion 2018 Annual Sales: $8.3 Billion = Gilead (Harvoni, Epclusa, Sovaldi, Vosevi) = Merck (Zepatier) m J&J (Olysio) m AbbVie (Viekira, Mavyret) mAbbVie (Viekira, Mavyret) = Gilead (Harvoni, Epclusa, Sovaldi, Vosevi) = Merck (Zep
Slide 12: CC-31244: Broad Spectrum HCV Non-Nucleoside Inhibitor (NNI)
Akt ; a }@l CC-31244: Broad Spectrum HCV Non-Nucleoside Inhibitor (NNI) ~ Next Generation Combination Therapy HCV GT1—GT6 NS5B Polymerase Crystals + Potential best-in-class HCV NNI with a strong profile : oF « Broad spectrum, potent NSSB polymerase inhibitor ie + High barrier to drug resistance Be,
Slide 13: Potential Best-in-Class NNI
ae }@1 Potential Best-in-Class NNI xT CC-31244 > Genotypes 1-6 > 400 => (3.0) ABT-333 (Dasabuvir)' Genotype 1 400 BID (1.08) 800 BID (0.95) GS-9190 (Tegobuvir) Genotype 1 40 BID (1.0) 120 BID (1.5) 1. Represents approved DAA 13
Slide 14: CC-31244: Phase 2a University of Maryland Study Design
Ake Lot CC-31244: Phase 2a University of Maryland Study Design Open-label, Phase 2a study evaluating the safety, tolerability and preliminary efficacy of CC-31244 with approved HCV DAAs (HCV GT1 subjects, N=12) Sofosbuvir and Follow-Up at Velpatasvir 12 & 24 Weeks @o———- 4 Weeks ——_® CC-31244 (400 m
Slide 15: University of Maryland Phase 2a
Ake Lot University of Maryland Phase 2a Cocrystal Pharma announced safety and preliminary efficacy data for its U.S. Phase 2a study evaluating CC-31244 for the ultra-short treatment of HCV infected individuals: All subjects completed the 6-week treatment regimen The treatment was well tolerated with
Slide 16: Positive Phase 2a Results Demonstrated Ability to Identify Patients
PN }@1 Positive Phase 2a Results Demonstrated Ability to Identify Patients ‘\” More Likely to Respond to Ultrashort Treatment of HCV * 8 of 12 (67%) patients achieved primary endpoint of sustained virologic response (SVR) 12, which is considered a cure * 6 weeks of Epclusa’s therapy combined with on
Slide 17: Overview | Antiviral Programs: Influenza
17 Overview | Antiviral Programs: Influenza
Slide 18: Significant Unmet Need in Growing Influenza Market
Ake Lot Significant Unmet Need in Growing Influenza Market Global influenza market was valued at nearly $5.6 billion in 2017 and is expected to reach nearly $6.5 billion by 2022' Seasonal and pandemic infection 3-5 Million cases of severe illness annually" 1 Billion Up to 650,000 cases annually? dea
Slide 19: Influenza Remains a Major Global Concern
A, ~ SS oe ( Influenza Remains a Major Global Concern Flu season deaths top 80,000 last year, CDC says September27, 2018 US on track for one of TV. the worst flu seasons in decades Jan, 6, 2020 SCIENCE Child Flu Deaths Hit Record High for This Time of Year Jan. 7, 2020 Flu Season Off To Early Start,
Slide 20: Influenza Drug Candidates
Ake Lot Influenza Drug Candidates Influenza A/B Inhibitor Svat? Proprietary Influenza A and B Crystals «3 MERCK Collaboration ¢ Broad spectrum, potent dual influenza A/B preclinical lead will be developed « Result of Cocrystal’s drug discovery platform technology « Binds to highly conserved site of
Slide 21: Influenza Drug Candidates
Ake Lot Influenza Drug Candidates Antiviral Product Candidates Target All Strains of the Influenza A Virus Influenza A Inhibitor Influenza PB2 Lead a Binds to the highly conserved m7GTP binding pocket of PB2 Exhibits broad spectrum activity against seasonal and pandemic influenza strains, EC50 is 0.
Slide 22: Strong Synergistic Effects With Approved Influenza Antivirals
yer c ae tical al Strong Synergistic Effects With Approved ‘«e_ Influenza Antivirals Polymerase Inhibitor Favipiravir t Cocrystal 42344 2+ @~@: PA Inhibitor Neuraminidase Inhibitor
Slide 23: CC-42344: Pharmacological, Safety, Toxicity, and PK Evaluations
CC-42344: Pharmacological, Safety, Toxicity, and PK Evaluations Completed To Date GBECEEEB6BB6B6E66B88 B6BBEB In vitro antiviral profiling against seasonal and pandemic influenza A strains Cytotoxicity including larger screen: HepG2/high content analysis and 13 cell lines Caco-2 bidirectional permea
Slide 24: Overview | Antiviral Programs: Norovirus
24 Overview | Antiviral Programs: Norovirus
Slide 25: Norovirus is an Area of Significant Unmet Need
uN ( Norovirus is an Area of Significant Unmet Need Norovirus Market Overview Known Causes of Foodborne Illness Outbreaks, « No approved antiviral drugs for the treatment of Noro infection Parasites 1% Other Norovirus $4.2 billion in direct health system costs’ pas 700 million 19-21 million cheryl i
Slide 26: Cocrystal's Norovirus Program
Ake Lot Cocrystal’s Norovirus Program Norovirus sa NNI Program Noro Polymerase NNIs Norovirus and oraalk Polymerase Crystals Potential first-in-class NNI Potent and broad spectrum Noro polymerase inhibitors Technology platform complete Structure-based lead discovery ongoing
Slide 27: Intellectual Property
mS Lot Intellectual Property Patents and pending applications in the areas primarily related to the treatment of HCV, influenza A and influenza A/B * HCV Treatment » NS5B (non-nucleoside inhibitor) * Issued patents in U.S. « Pending applications in U.S., Australia, Brazil, Canada, China, Europe, Eur
Slide 28: Well-Positioned for Growth
28 Well-Positioned for Growth
Slide 29: Financial Snapshot
y Financial Snapshot: NASDAQ: COCP ~$25M 38.6MM ~302K Common shares Average daily 1 ETE GETD outstanding volume’ 9 Capitalization Table (As of January 31,2020) | # of Shares WAEP ee Common Shares Outstanding (Directors, Officers and 15,231,113 38.26% Affiliates) Common Shares Outstanding (Other) 23,
Slide 30: Strategy Directed at Advancing Programs and Growing Value
Ake Lot Strategy Directed at Advancing Programs and Growing Value ¢ Growth in focused therapeutic areas * Continue to progress an innovative pipeline ¢ Form additional strategic collaborations and partnerships * Ongoing collaboration with Merck expected to accelerate influenza A/B development progra
Slide 31: Upcoming Milestones Expected to Drive Value
uN Lot Upcoming Milestones Expected to Drive Value Q2 2019 Influenza A Commence GLP Toxicology Studies Q3 2019 Influenza Present Preclinical Data at ISIRV ee Present at 26" International Symposium on Hepatitis C Virus and Related Viruses Q4 2019 Present Data at HCV 2019 and AASLD Scientific Conferen
Slide 32: Thank you!
C¥CRYS TA L Thank you! PHARMA,IN
Cocrystal Pharma — Investor Presentation (February 2020) on 6ix